Cabozantinib is indicated for the treatment of patients with advanced Renal Cell Carcinoma (RCC) as first line treatment in combination with nivolumab. Monotherapy in 2nd Line in RCC.
30 coated tablets
Products which continue to have a valid patent protection at present are manufactured in line with the current laws of the Argentine Republic. Please, take into account that our products will only be shipped to countries where the substance and its use are not protected by patents.
NOTICE The legal content included on this site was designed exclusively to meet the needs of the health-care professionals for the adequate use of the pharmaceutical products. It does not contain promotional information. All the texts referring to our prescription products are compliant with the guidelines approved by ANMAT, the Argentine administration for drugs, food and medical technology. Laboratorios Richmond always recommends consulting a qualified health-care professional if you have doubts regarding any given medicalI understand and wish to see the information